GLP-1 Pills: Novo Nordisk vs. Eli Lilly

What's Actually Happening Between Novo Nordisk and Eli Lilly

If you follow weight loss medication news, you have probably heard that the two biggest names in GLP-1 drugs are Novo Nordisk and Eli Lilly. Novo Nordisk makes Ozempic and Wegovy. Eli Lilly makes Mounjaro and Zepbound.

For the past couple of years, Eli Lilly has been seen as the company with the edge, largely because tirzepatide (the active ingredient in Mounjaro and Zepbound) has shown stronger average weight loss results in clinical trials compared to semaglutide. But now, Novo Nordisk is making a move that investors and patients alike are starting to pay attention to: oral GLP-1 medications.

Novo Nordisk already has experience with an oral semaglutide tablet called Rybelsus, which is approved for type 2 diabetes. The next wave of development is pushing toward oral formulations that are potent enough to drive significant weight loss, not just blood sugar control. Eli Lilly is working on this too, but Novo Nordisk appears to be further along in the pipeline.

Why an Oral GLP-1 Pill Matters for Patients

Right now, the most effective GLP-1 medications for weight loss are injections. Wegovy and Zepbound are both weekly self-injections. For many people, that works fine. But for others, needles are a genuine barrier.

Surveys consistently show that a meaningful percentage of patients either delay starting GLP-1 therapy or stop it entirely because of injection anxiety. An effective oral option could bring GLP-1 treatment to a much larger group of people who otherwise would not pursue it.

There is also a practical convenience angle. Pills do not require refrigeration the same way injectables do. They are easier to travel with and simpler to incorporate into a daily routine alongside other medications.

What We Know About Oral Semaglutide for Weight Loss

Rybelsus (oral semaglutide, 7mg and 14mg doses) is already FDA-approved, but specifically for type 2 diabetes, not weight management. At current approved doses, it does not produce the same level of weight loss seen with weekly injectable semaglutide (Wegovy).

Novo Nordisk is working on higher-dose oral formulations and improved delivery mechanisms that could close that gap. Early data on some of these next-generation oral candidates has been promising, but it is important to note that none of these newer formulations are FDA-approved for weight loss yet.

The key challenge with oral GLP-1s is bioavailability. GLP-1 molecules are proteins that break down in the digestive tract before they can be absorbed. Getting enough of the drug into the bloodstream through a pill requires either much higher doses or special delivery systems to protect the molecule. This is the scientific hurdle both companies are racing to solve.

Where Eli Lilly Stands Right Now

Eli Lilly's tirzepatide still holds real advantages. In the SURMOUNT clinical trial program, tirzepatide delivered average body weight reductions of up to 22.5% in some participants, which remains among the highest results reported for any approved weight loss medication.

Eli Lilly is also developing an oral version of tirzepatide, as well as other next-generation obesity drugs including orforglipron, a small-molecule oral GLP-1 receptor agonist. Orforglipron does not face the same bioavailability challenges as peptide-based GLP-1s because it is a small molecule, not a protein. Early trial data has shown meaningful weight loss results, and Eli Lilly is moving it through late-stage trials.

So while Novo Nordisk may be ahead on oral semaglutide specifically, Eli Lilly has its own oral candidates in development. The competition is real, and it is not a simple case of one company winning outright. For patients, both pipelines matter.

What This Means for the Cost of GLP-1 Medications

One of the biggest concerns for anyone considering GLP-1 medications right now is cost. Injectable semaglutide and tirzepatide carry list prices well above $1,000 per month without insurance. Insurance coverage varies widely, and many plans still exclude obesity drugs entirely.

Increased competition tends to bring prices down over time, especially when products are competing in the same therapeutic category. If both Novo Nordisk and Eli Lilly bring effective oral GLP-1 options to market, the competitive pressure could push both companies to be more aggressive on pricing and patient access programs.

However, that is a longer-term scenario. In the near term, if you are paying out of pocket or dealing with limited insurance coverage, the situation has not changed dramatically yet. Manufacturer savings cards and compounding pharmacy options (where legally available) remain the most practical ways to reduce costs today.

You can compare current options and savings through the GLP-1 Coupons page and review which providers offer the best access through the Best Providers comparison tool.

Current GLP-1 Medications at a Glance

Here is a quick comparison of where the major GLP-1 medications stand right now, to give context to this competitive shift.

Prices are approximate list prices and vary by dose, pharmacy, and insurance. Always verify current pricing with your pharmacy or provider.

The Oral GLP-1 Pipeline: What to Watch For

For anyone thinking about this from a patient perspective, here is a practical breakdown of what is actually in development and when it might matter.

Novo Nordisk's Oral Candidates

Novo Nordisk has been testing higher-dose oral semaglutide formulations specifically aimed at weight management. They are also exploring co-formulations that pair semaglutide with other compounds to improve absorption. Some of these are in Phase 2 or Phase 3 clinical trials as of 2025.

The company has decades of experience with semaglutide, which gives it an advantage in understanding how to optimize this molecule. That institutional knowledge is part of what gives Novo Nordisk its current head start on the oral side.

Eli Lilly's Oral Candidates

Eli Lilly's most closely watched oral candidate is orforglipron, a non-peptide GLP-1 receptor agonist. Because it is a small molecule (not a protein), it can be absorbed orally without the same degradation issues. Phase 2 data published in 2023 in the New England Journal of Medicine showed weight loss of up to 14.7% over 36 weeks in adults with obesity, which is a meaningful result for an oral drug.

Eli Lilly is also pursuing an oral version of tirzepatide, though that program is earlier in development.

Should You Wait for a GLP-1 Pill?

This is one of the most practical questions patients ask when this topic comes up. The honest answer: probably not, if you qualify for treatment now.

Clinical development timelines are unpredictable. A drug that looks promising in Phase 2 may face setbacks in Phase 3. Regulatory review takes additional time. Even in an optimistic scenario, a newly approved oral GLP-1 for weight loss could still be two or more years away from being available at your pharmacy.

Obesity is a chronic medical condition with real health consequences, including increased risk of cardiovascular disease, type 2 diabetes, sleep apnea, and joint problems. Waiting on a future medication while declining current treatment carries its own risks.

If needle anxiety is your primary concern, talk to your provider about whether Rybelsus might be an option, even though it is not approved specifically for weight loss. Your doctor can weigh the off-label considerations with you. And if cost is the barrier, use the GLP-1 Coupons page and Best Providers comparison to find more affordable access.

Questions to Ask Your Doctor About Oral GLP-1s

If you bring this topic up at your next appointment, here are specific questions that will lead to a productive conversation.

1. Given that oral GLP-1 formulations for weight management are not yet FDA-approved, is there a clinical case for me to try Rybelsus off-label for weight loss now, or does my health profile make the injectable forms a clearly better starting point?
2. How do you weigh the bioavailability difference between oral and injectable semaglutide when thinking about my specific weight loss goals, and what realistic outcomes should I expect if we go the oral route?
3. If I start on an injectable GLP-1 now and a well-studied oral option becomes FDA-approved in the next year or two, how straightforward would the transition be, and would we need to re-titrate from the beginning?
4. Are you familiar with Eli Lilly's orforglipron and its Phase 2 data, and do you think that class of small-molecule oral GLP-1s could be a better fit for me than a peptide-based oral option if and when it reaches approval?
5. If needle anxiety is my main barrier to starting injectable therapy, are there specific injection technique tips, device options, or behavioral strategies you would recommend to make weekly injections more manageable in practice?
6. What is your current assessment of the oral GLP-1 pipeline timeline, and at what point of development would you feel comfortable recommending I wait for an oral option rather than starting an injectable now?

These questions signal that you are informed and help your provider give you more specific, personalized guidance rather than a generic overview.